Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 11, Pages 4615-4628Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm500064t
Keywords
-
Categories
Funding
- Minnesota Supercomputing Insititute
- NIH [RO1DK064250, R01DK091906, RO1DA031370]
- State of Florida, Executive Office of the Governor's Office of Tourism, Trade, and Economic Development
Ask authors/readers for more resources
Human obesity has been linked to genetic factors and single nucleotide polymorphisms (SNPs). Melanocortin-4 receptor (MC4R) SNPs have been associated with up to 6% frequency in morbidly obese children and adults. A potential therapy for individuals possessing such genetic modifications is the identification of molecules that can restore proper receptor signaling and function. These compounds could serve as personalized medications improving quality of life issues as well as alleviating diseases symptoms associated with obesity including type 2 diabetes. Several hMC4 SNP receptors have been pharmacologically characterized in vitro to have a decreased, or a lack of response, to endogenous agonists such as alpha-, beta-, and gamma(2)-melanocyte stimulating hormones (MSH) and adrenocorticotropin hormone (ACTH). Herein we report the use of a mixture based positional scanning combinatorial tetrapeptide library to discover molecules with nM full agonist potency and efficacy to the L106P, 169T, I102S, A219V, C271Y, and C271R hMC4Rs. The most potent compounds at all these hMC4R SNPs include Ac-His-(pI)DPhe-Tic-(pNO(2))DPhe-NH2, Ac-His-(pCl)DPhe-Tic-(pNO(2))DPhe-NH2, Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2, and Ac-Arg-(pCl)DPhe-Tic-(pNO(2))DPhe-NH2, revealing new ligand pharmacophore models for melanocortin receptor drug design strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available